Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma

Table 1 Treatment response and survival rate of hepatic arterial infusion chemotherapy

Group	No.	Treatment regimen	Response rate (CR + PR)	Median survival
Toyoda et al[20]	21	Cisplatin: 5-10 mg 5-FU: 500 mg	14.3%	36-549 d
Sumie et al[21]	16	Group 1: Cisplatin 10 mg + 5-FU : 250 mg (5 d)	56.3%	2.7 yr
	21	Group 2: TACE with epirubicin	23.8%	1.7 yr
Kim et al[22]	36	Group 1: 5-FU 500 mg/m2 on D 1-3 + Cisplatin 60 mg/m2 on D2	16.7% (PR16.7%)	193 d
	31	Group 2: TACE with doxorubicin (10-60 mg)	0%	119 d
Hamada et al[23]	88	Cisplatin: 10 mg 5-FU: 1000 mg	17% (CR1%/PR16%)	19.5 mo
Lin et al[24]	53	Cisplatin: 10 mg, 5-FU 100 mg, Mitomycin 2 mg Leucovorin 15 mg	28.3%	NA
Hwang et al[25]	18	5-FU 330 mg/m2 every week Epirubicin 30 mg/m2 Mitomycin-C 2.7 mg/m2 every 2 wk	38.9% (PR 38.9%)	8 mo
Sim et al[30]	67	Group 1: Cisplatin: 80 mg/m2 (1 d)	20% (CR2.5%/PR17.5%)	5 mo
	36	Group 2: Cisplatin: 60 mg/m2 (1 d) + 5-FU 500 mg/m2 (3 d)	19.2% (CR 3.8%/PR15.4%)	8.5 mo
Lim et al[31]	40	Group 1: Cisplatin 10 mg + 5-FU 250 mg (5 d)	3.8%(PR 3.8%)	5 mo
	39	Group 2: Conservative care	0%	3 mo
Woo et al[26]	36	Group 1 (High dose): 5-FU 500 mg/m2 on D 1-3 + Cisplatin 60 mg/m2 on D2	16.7% (PR 16.7%)	193 d
	32	Group 2 (Low dose): 5-FU 170 mg/m2 on D 1-5 + Cisplatin 7 mg/m2 on D 1-5	0%	153 d
Yamashita et al[27]	57	Group 1 (IFN/FU): 5-FU 300 mg/m2 per day for 5 d for 1st 2 wk + IFNα-2b 3M U IM 3 times/wk for 4 wk	45.6% (CR 1.7%/PR 43.9%)	10.5 mo
	57	Group 2 (IFN/FU + Cisplatin): IFN/FU + Cisplatin 20 mg/m2 on day 1, 8	24.6% (CR 5.3%/PR 19.3%)	17.6 mo
Nouso et al[28]	476	Group 1: Cisplatin + 5-FU	40.5%	14.0 mo
	1466	Group 2: No therapy	(CR 4.0%/PR 36.5%)	5.2 mo
Song et al[29]	50	Group 1: Cisplatin + 5-FU ± epirubicin	24.0%	7.1 mo
	60	Group 2: Sorafenib	13.3%	5.5 mo

NA: Not available; 5-FU: 5-fluorouracil.